Table 1. Mean (standard deviation) change in binding potential from baseline in MP+LPS, MP+PBO, LPS pre-treatment conditions.

ROI	Volume (mL)	Mean ΔBP (n=8)		P-value	Mean ΔBP (n=2)
		MP+LPS	MP+PBO		LPS
Striatum	42.6	17.1 (3.6)	8.8 (3.6)	0.007	6.1 (1.8)
Putamen	21.9	17.9 (5.0)	9.5 (4.5)	0.013	4.5 (3.2)
Left	10.7	18.0 (5.4)	9.7 (7.5)	0.071	4.7 (0.1)
Right	11.3	17.7 (5.6)	9.1 (4.9)	0.001	4.6 (5.6)
Caudate	20.7	16.1 (5.4)	7.7 (3.7)	0.020	8.6 (0.2)
Left	10.2	13.9 (7.8)	4.8 (9.2)	0.099	9.6 (3.3)
Right	10.5	18.5 (5.3)	11.0 (11.6)	0.058	7.3 (3.7)
Ventral striatum	2.9	12.7 (8.1)	11.4 (9.3)	0.809	1.7 (5.4)
Left	1.4	16.6 (7.1)	11.5 (11.4)	0.409	3.9 (7.5)
Right	1.5	7.3 (13.8)	10.8 (13.5)	0.574	−1.3 (2.9)

Abbreviations: ΔBP, change in binding potential; LPS, lipopolysaccharide; MP, methylphenidate; PBO, placebo.